Integrated Annual Report

Overview

The report presents Torrent Pharma's FY2023-24 performance, including consolidated revenue of INR 10,728 crores and continued growth across its branded and generic businesses. It highlights a 29.31% reduction in Scope 1 and Scope 2 emissions since 2020, supported by renewable-energy projects, biomass boilers, and energy-efficiency measures. The company also reports community-health outreach across more than 600 villages, with more than 31,000 children screened during the year.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2023-2024
Period: 1 April 2023 – 31 March 2024
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services